biostudies-literatureUnknown12Chae H<h4>Objective</h4>The lack of a clear and unified definition of shared decision-making (SDM) may hinder its effective application in oncology care. This study aims to clarify the concept of SDM specifically in the context of early-stage breast cancer treatment through an evolutionary concept analysis.<h4>Methods</h4>A systematic search was conducted across PubMed, CINAHL, PsycINFO, Cochrane, and EMBASE databases for articles published from January 2015 to December 2024. Using keywords "shared decision-making" and "breast cancer," relevant studies were identified, and key attributes of SDM were extracted and synthesized. Sixteen studies met the inclusion criteria.<h4>Results</h4>SDM for early-stage breast cancer treatment was characterized by 10 attributes spanning three levels: 1) Patient perspective: involvement in decision-making, values and preferences regarding treatment options, and deliberative thinking to achieve choice certainty; 2) Healthcare professional perspective: provision of individualized information, psychological support, consultation focused on patients' best interests, collaborative partnerships with patients, coordinated care delivery, and promotion of person-centered, informed choices; 3) Healthcare system level: fostering a patient-centered healthcare culture.<h4>Conclusions</h4>These findings provide a comprehensive conceptual framework to guide the development of detailed SDM guidelines tailored for early-stage breast cancer patients. Enhanced understanding of SDM can support nurses and healthcare professionals in facilitating collaborative and optimal decision-making processes within oncology care. Furthermore, this study lays the groundwork for developing measurement tools and disease-specific interventions to advance SDM implementation in early-stage breast cancer treatment.<h4>Systematic review registration</h4>PROSPERO (CRD42024587218).Asia-Pacific journal of oncology nursing100775https://www.ebi.ac.uk/biostudies/studies/S-EPMC12409458biostudies-literatureShared decision-making for early-stage breast cancer treatment: An evolutionary concept analysis.PMC12409458Ji HJChae HLee YMoon HSon YJfalseShared decision-making for early-stage breast cancer treatment: An evolutionary concept analysis.<h4>Objective</h4>The lack of a clear and unified definition of shared decision-making (SDM) may hinder its effective application in oncology care. This study aims to clarify the concept of SDM specifically in the context of early-stage breast cancer treatment through an evolutionary concept analysis.<h4>Methods</h4>A systematic search was conducted across PubMed, CINAHL, PsycINFO, Cochrane, and EMBASE databases for articles published from January 2015 to December 2024. Using keywords "shared decision-making" and "breast cancer," relevant studies were identified, and key attributes of SDM were extracted and synthesized. Sixteen studies met the inclusion criteria.<h4>Results</h4>SDM for early-stage breast cancer treatment was characterized by 10 attributes spanning three levels: 1) Patient perspective: involvement in decision-making, values and preferences regarding treatment options, and deliberative thinking to achieve choice certainty; 2) Healthcare professional perspective: provision of individualized information, psychological support, consultation focused on patients' best interests, collaborative partnerships with patients, coordinated care delivery, and promotion of person-centered, informed choices; 3) Healthcare system level: fostering a patient-centered healthcare culture.<h4>Conclusions</h4>These findings provide a comprehensive conceptual framework to guide the development of detailed SDM guidelines tailored for early-stage breast cancer patients. Enhanced understanding of SDM can support nurses and healthcare professionals in facilitating collaborative and optimal decision-making processes within oncology care. Furthermore, this study lays the groundwork for developing measurement tools and disease-specific interventions to advance SDM implementation in early-stage breast cancer treatment.<h4>Systematic review registration</h4>PROSPERO (CRD42024587218).2025-01-01T00:00:00Z2025 Dec2026-06-03T02:17:56.437Z2026-04-23T03:09:44.432ZS-EPMC124094584091944410.1016/j.apjon.2025.100775